Hoth Therapeutics (HOTH) Stock Price, News & Analysis

Company Overview

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Key Stats

• Today's Range: $1.23 to $1.30
• 50-Day Range: $1.13 to $1.49
• 52-Week Range: $0.65 to $3.80
• Volume: 126,270 shs
• Average Volume: 3.97 million shs
• Market Capitalization: $17.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Hoth Therapeutics Stock Analysis - MarketRank™

Hoth Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 507th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Hoth Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Hoth Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Hoth Therapeutics are expected to grow in the coming year, from ($1.36) to ($0.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hoth Therapeutics is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hoth Therapeutics is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Hoth Therapeutics has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.32% of the float of Hoth Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Hoth Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hoth Therapeutics has recently decreased by 23.99%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hoth Therapeutics does not currently pay a dividend.

Dividend Growth

Hoth Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.32% of the float of Hoth Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Hoth Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hoth Therapeutics has recently decreased by 23.99%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.33

News Sentiment

Hoth Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Hoth Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for HOTH on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hoth Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.92% of the stock of Hoth Therapeutics is held by insiders.

Percentage Held by Institutions

Only 7.08% of the stock of Hoth Therapeutics is held by institutions.

HOTH Stock Analysis - Frequently Asked Questions

How have HOTH shares performed this year?

Hoth Therapeutics' stock was trading at $0.7481 at the beginning of the year. Since then, HOTH stock has increased by 70.4% and is now trading at $1.2750.

How were Hoth Therapeutics' earnings last quarter?

Hoth Therapeutics, Inc. (NASDAQ:HOTH) posted its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.10.

When did Hoth Therapeutics' stock split?

Hoth Therapeutics's stock reverse split on Wednesday, October 26th 2022.The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Hoth Therapeutics IPO?

Hoth Therapeutics (HOTH) raised $8 million in an IPO on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

Who are Hoth Therapeutics' major shareholders?

Top institutional investors of Hoth Therapeutics include Geode Capital Management LLC (0.93%).
View institutional ownership trends.

How do I buy shares of Hoth Therapeutics?

Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Hoth Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hoth Therapeutics investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Ford Motor (F), Meta Platforms (META), NVIDIA (NVDA) and Zomedica (ZOM).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HOTH
• CIK: 1711786
• Web: www.hoththerapeutics.com
• Phone: (646) 756-2997
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Hoth Therapeutics: $4.00
• High Price Target: $5.00
• Low Price Target: $3.00
• Potential Upside/Downside: +220.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.19 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -114.32%
• Return on Assets: -105.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.54
• Quick Ratio: 27.54

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.73 per share
• Price / Book: 1.71

Miscellaneous

• Outstanding Shares: 13,260,000
• Free Float: 12,341,000
• Market Cap: $16.58 million
• Optionable: Not Optionable
• Beta: 0.66